Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05716087
PHASE2

A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma

Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD.

View on ClinicalTrials.gov

Summary

This is an open-label, single arm, multi-center Phase 2 study of oral Rocbrutinib in patients with mantle cell lymphoma who are failed or relapsed after remission or intolerated to Bruton's tyrosine kinase (BTK) inhibitor.

Official title: An Open Label, Single Arm, Multicenter Phase II Study of the Efficacy and Safety of Rocbrutinib Monotherapy for Recurrent or Refractory Mantle Cell Lymphoma

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

62

Start Date

2023-02-21

Completion Date

2026-06-30

Last Updated

2026-01-15

Healthy Volunteers

No

Interventions

DRUG

Rocbrutinib

Subjects to take Rocbrutinib tablets orally with 240mL water, without food, Once daily.The treatment will continue until progressive disease, unacceptable toxicity, etc.

Locations (43)

Anhui provincial cancer hospital

Hefei, Anhui, China

The first affiliated hospital of Anhui medical university

Hefei, Anhui, China

Peking University Third Hospital

Beijing, Beijing Municipality, China

Beijing Cancer Hospital

Beijing, Beijing Municipality, China

The first affiliated hospital of Chongqing mediacal university

Chongqing, Chongqing Municipality, China

Fujian Cancer Hospital

Fuzhou, Fujian, China

Fujian Medical university union hospital

Fuzhou, Fujian, China

The first affiliated hospital of Xiamen university

Xiamen, Fujian, China

Gansu provincial cancer hospital

Lanzhou, Gansu, China

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China

Meizhou people'shospital

Meizhou, Guangdong, China

The First Affiliated Hospital of Guangxi Medical University

Nanning, Guangxi, China

The fourth hospital of Hebei medical university

Shijiazhuang, Hebei, China

Harbin First Hospital

Harbin, Heilongjiang, China

The First Affiliated Hospital of Henan University of Science & Technology

Luoyang, Henan, China

Henan Cancer Hospital

Zhengzhou, Henan, China

Henan provincial people's hospital

Zhengzhou, Henan, China

The first affiliated hospital of Zhengzhou university

Zhengzhou, Henan, China

Hunan cancer hospital

Changsha, Hunan, China

Jiangsu cancer hospital

Nanjing, Jiangsu, China

Jiangsu province hospital

Nanjing, Jiangsu, China

The first affiliated hospital of Nanchang university

Nanchang, Jiangxi, China

The second hospital of dalian medical university

Dalian, Liaoning, China

Shengjing hospital of China medical university

Shenyang, Liaoning, China

The first hospital of China medical university

Shenyang, Liaoning, China

Qilu hospital of Shandong university

Jinan, Shandong, China

Shandong Cancer Hospital

Jinan, Shandong, China

West China School of Medicine

Chengdu, Sichuan, China

Tianjin Hematonosis Hospital

Tianjin, Tianjin Municipality, China

Tianjin medical university cancer hospital

Tianjin, Tianjin Municipality, China

Zhejiang Cancer Hospital

Hangzhou, Zhejiang, China

Affiliated hospital of hebei university

Baoding, China

Beijing Boren Hospital

Beijing, China

Beijing Friendship hospital

Beijing, China

The First Bethune Hospital of Jilin University

Changchun, China

Sichuan Cancer Hospital

Chengdu, China

The First People's Hospital of Foshan

Foshan, China

Nanfang Hospital, Southern Medical University

Guangzhou, China

Sun Yat-sen Memorial Hospital

Guangzhou, China

The First Affiliated Hospital of Soochow University

Suzhou, China

The first affiliated hospital of Wenzhou medical university

Wenzhou, China

Hubei Cancer Hospital

Wuhan, China

Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology

Wuhan, China